Publication: 3995

Publication: 3995

Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: J Natl Cancer Inst vol 116 (1) 115-126

Year:: 2023
Type:: Manuscript
Funding:: NCTN
Endpoint:: Secondary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pmc-release

Note:

Methodological:: No
Biospecimen:: Yes
SDC:: No
Book Volume:: 13

Parents:: None
Children:: None

Program:: TRP
Primary Committee:: Correl Sci NOS
Sec. Committees:: GU

Pharmas:: Sanofi-Aventis
Grants:: U10CA180821, U10CA180882, U24 CA196171, UG1CA233180, UG1CA233253, UG1CA233290, U10CA180863 (Canadian Cancer Trials Group) , R01 CA256157, R01 CA249279, W81XWH-17-1-0653, R37 CA24148601A1, 5U01CA157703

Corr. Author:
Authors:: Takayuki Sumiyoshi Xiaofei Wang Evan W Warner Andrea Sboner Matti Annala Michael Sigouros Kevin Beja Kei Mizuno Shengyu Ku Ladan Fazli James Eastham Mary-Ellen Taplin Jeffrey Simko Susan Halabi Michael J Morris Martin E Gleave Alexander W Wyatt Himisha Beltran

Networks:: LAPS-MA036, LAPS-NY016

Study: CALGB-90203
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords:: Article, AcademicSubjects/MED00010